Predicted to enable mRNA binding activity and pre-mRNA binding activity. Involved in negative regulation of gene expression; negative regulation of type B pancreatic cell apoptotic process; and response to insulin. Predicted to be located in nuclear speck. Predicted to be part of ribonucleoprotein complex. Predicted to be active in cytoplasm and nucleus. Human ortholog(s) of this gene implicated in proliferative diabetic retinopathy and spermatogenic failure 3. Orthologous to human SRSF6 (serine and arginine rich splicing factor 6); PARTICIPATES IN spliceosome pathway; INTERACTS WITH 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine; aconitine.
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRSF6 mRNA
SRPK1 protein affects the reaction [Paraquat results in increased phosphorylation of SRSF6 protein] and SRPK2 protein affects the reaction [Paraquat results in increased phosphorylation of SRSF6 protein]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRSF6 mRNA
GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim.
Insulin regulates alternative splicing of protein kinase C beta II through a phosphatidylinositol 3-kinase-dependent pathway involving the nuclear serine/arginine-rich splicing factor, SRp40, in skeletal muscle cells.
Serine arginine splicing factor 3 is involved in enhanced splicing of glucose-6-phosphate dehydrogenase RNA in response to nutrients and hormones in liver.